Prolonging Remission with Rituximab Maintenance Therapy

Seminars in Oncology

Volumn 31, Issue 1 SUPPL. 2, 2004, Pages 17-21

  Hainsworth, John D ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RITUXIMAB;

B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INTERMETHOD COMPARISON; LYMPHATIC LEUKEMIA; MAINTENANCE THERAPY; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL TIME;

EID: 1542513764     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.12.005     Document Type: Conference Paper

References (11)

1. Hainsworth JD, Litchy S, Burris HA III, et al: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20:4261-4267, 2002
2. Hainsworth JD, Litchy S, Barton JH, et al: Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21:1746-1751, 2003
3. Colombat P, Salles G, Brousse N, et al: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumour burden: Clinical and molecular evaluation. Blood 97:101-106, 2001
4. Witzig TE, Vukov AM, Habermann TM, et al: Rituximab therapy for patients with newly diagnosed, asymptomatic advanced-stage follicular grade I non-Hodgkin's lymphoma (NHL): A phase II trial in the North Central Cancer Treatment Group (NCCTG). Blood 100, 2002 (abstr)
5. Czuczman MS, Grillo-López AJ, White CA, et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999
6. Czuczman MS, Fallon A, Mohr A, et al: Phase II study of rituximab plus fludarabine in patients (pts) with low-grade lymphoma (LGL): Final report. Blood 98:601a, 2001 (suppl 1) (abstr)
7. Hiddemann W, Dreyling M, Unterhalt M, for the German Low Grade Lymphoma Study Group: Rituximab plus chemotherapy in follicular and mantle cell lymphomas. Semin Oncol 30:16-20, 2003 (suppl 2)
8. McLaughlin P, Rodriguez MA, Hagemeister FB, et al: Stage IV indolent lymphoma: A randomized study of concurrent vs. sequential use of FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) and rituximab (R) monoclonal antibody therapy, with interferon maintenance. Proc Am Soc Clin Oncol 22:564, 2003 (abstr)
9. Davis TA, Grillo-López AJ, White CA, et al: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol 18:3135-3143, 2000
10. Hainsworth JD, Litchy S, Morrissey L, et al: Rituximab as first-line and maintenance therapy for indolent non-Hodgkin's lymphoma: Long-term follow-up of a Minnie Pearl Cancer Research Network phase II trial. Blood 102:411a, 2003 (abstr 1496)
11. Ghielmini M, Schmitz SFH, Cogliatti S, et al: Prolonged treatment with rituximab significantly improves event free survival and duration of response in patients with follicular lymphoma: A randomized SAKK Trial. Blood 100:161a, 2002 (abstr)